In 2022, WHO recorded that 43% of adults (18 years and above) globally were overweight and 16% were living with obesity
Course Highlights Discover how combining lifestyle modifications with GLP-1 receptor agonists can improve weight loss, glycemic control, and overall cardiometabolic health Examine the science behind GLP-1 receptor agonists, from their effects on insulin secretion and appetite regulation to next-generation agents like tirzepatide and orforglipron Learn best practices for patient education, dosing strategies, and interprofessional collaboration while addressing contraindications, adverse effects, and compounding warnings Introduction Obesity is a chronic and prevalent condition that impacts health, contributing to higher rates of morbidity and mortality
The most obvious answer is make-up
Long-term intake of a high protein diet modulates liver steatosis and fat accumulation in OVX mice
Obesity is prevalent, affecting 40% of Americans age 20-plus and costing the economy nearly $1.4 trillion a year